STOCK TITAN

AM Best Affirms Credit Ratings of MetLife, Inc. and Its Life/Health Subsidiaries

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
AM Best has affirmed the Financial Strength Rating (FSR) of A+ (Superior) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of 'aa-' (Superior) of MetLife, Inc. (NYSE: MET), with a stable outlook. The ratings reflect MetLife's strong balance sheet strength, operating performance, business profile, and enterprise risk management. The organization has a strong and defensible market position in its core lines of business and diverse product offerings in various geographic markets.
Positive
  • AM Best has affirmed MetLife, Inc.'s Financial Strength Rating (FSR) of A+ (Superior) and Long-Term Issuer Credit Ratings (Long-Term ICR) of 'aa-' (Superior) with a stable outlook.
  • MetLife's strong balance sheet strength is supported by its consolidated holding company view of capital adequacy, financial flexibility, and liquidity of its ultimate parent (MetLife, Inc.).
  • The organization has a strong and defensible market position in its core lines of business and diverse product offerings in various geographic markets.
  • MetLife has a history of generating revenue growth and consistently positive operating metrics on a statutory and GAAP basis.
  • The ratings also reflect the organization's focus on enhancing its product offerings, concentration on higher margin product lines with steadier returns, and lower expenses.
Negative
  • None.

Insights

The affirmation of MetLife's Financial Strength Rating (FSR) and Long-Term Issuer Credit Ratings (Long-Term ICR) by AM Best signifies a strong vote of confidence in the company's financial stability and resilience. This assessment is critical for stakeholders, as it underscores MetLife's robust balance sheet, strong operating performance and sound enterprise risk management practices. The stable outlook attached to these ratings suggests that MetLife is expected to maintain its financial health over the medium term, which is reassuring for investors and policyholders alike.

From a financial analyst's perspective, MetLife's strategic focus on higher margin product lines and efforts to reduce liability risk are positive indicators of prudent financial management. The diversification of earnings geographically and across business lines reduces the company's exposure to market-specific risks and enhances its ability to withstand economic fluctuations. Furthermore, the appropriate levels of financial leverage and interest coverage ratios align with industry standards, supporting the company's creditworthiness.

The ratings affirmation reflects MetLife's strong market position and the diversity of its product offerings. A market research analyst would note that MetLife's defensible positions in core lines of business, particularly in the United States, Asia, Latin America and the EMEA region, provide a competitive edge and facilitate growth opportunities. The company's well-diversified earnings streams, stemming from its geographic reach and distribution channels, suggest resilience against market-specific downturns and the ability to capitalize on regional growth trends.

Moreover, the focus on product enhancement and concentration on higher margin lines with steadier returns indicates a strategic shift towards optimizing the product mix to meet changing consumer demands and market conditions. This adaptability is crucial in the dynamic insurance industry where consumer preferences and regulatory landscapes are constantly evolving.

AM Best's recognition of MetLife's appropriate enterprise risk management (ERM) practices highlights the company's commitment to identifying, assessing and managing risks effectively. A risk management consultant would emphasize the importance of MetLife's ongoing improvements to its ERM framework, which includes capital modeling and stress testing. These practices are essential for anticipating potential financial challenges and ensuring that the company has adequate capital buffers to absorb shocks.

The mention of risks associated with mortgage concentrations is a reminder of the need for continuous monitoring of credit exposures. The consultant would advocate for a proactive approach to managing these risks, especially given the potential for market volatility and changing interest rate environments. MetLife's historical trend towards reduced liability risk, particularly related to equity and interest rate risk, is indicative of a strategic de-risking effort which aligns with best practices in risk management.

OLDWICK, N.J.--(BUSINESS WIRE)-- AM Best has affirmed the Financial Strength Rating (FSR) of A+ (Superior) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of “aa-” (Superior) of the members of Metropolitan Life Insurance Group (collectively referred to as MetLife or the group). Concurrently, AM Best has affirmed the Long-Term ICR of “a-” (Excellent) and the Long- and Short-Term Issue Credit Ratings (Long-Term IR; Short-Term IR) of MetLife, Inc. (headquartered in New York, NY) [NYSE: MET]. The outlook of these Credit Ratings (ratings) is stable. (See below for a detailed listing of companies and Long- and Short-Term IRs.)

The ratings reflect MetLife’s balance sheet strength, which AM Best assesses as strong, as well as its strong operating performance, very favorable business profile and appropriate enterprise risk management (ERM).

MetLife’s strong balance sheet strength assessment is supported by its consolidated holding company view of capital adequacy that is enhanced by the financial flexibility and the liquidity of its ultimate parent (MetLife, Inc.), which historically has maintained steady levels of excess liquidity. Additionally, there has been a long-term trend toward reduced liability risk on MetLife’s balance sheet, related to equity and interest rate risk as MetLife’s product portfolio changes over time. MetLife’s financial leverage and interest coverage is at appropriate levels for the ratings. There are some risks with mortgage concentrations and AM Best will continue to monitor the group’s exposure in this regard.

The group has a history of generating revenue growth and consistently positive operating metrics on a statutory and GAAP basis. Earnings are well-diversified by geography, business line and distribution channel. Earnings volatility is lower within its group benefits segment. AM Best views the group’s operating performance as strong, with its focus on enhancing its product offerings, concentration on higher margin product lines with steadier returns and lower expenses. AM Best views the group’s ERM as appropriate, as it continues to focus on improving its overall program, capital modeling and stress testing.

The ratings also reflect the organization’s strong and defensible market positions in many of its core lines of business and the diversity in its product offerings and geographic markets in the United States, Asia and Latin America, as well as the Europe, Middle East and Africa region.

The FSR of A+ (Superior) and the Long-Term ICRs of “aa-” (Superior) have been affirmed with stable outlooks for the following subsidiaries of MetLife, Inc.:

  • Delaware American Life Insurance Company
  • Metropolitan Life Insurance Company
  • Metropolitan Tower Life Insurance Company
  • SafeGuard Health Plans, Inc. (TX)
  • SafeGuard Health Plans, Inc. (FL)
  • SafeGuard Health Plans, Inc. (CA)
  • MetLife Global Benefits, Ltd.
  • Metropolitan General Insurance Company

The following Short-Term IRs have been affirmed:

MetLife Funding, Inc.—
-- AMB-1+ (Strongest) on commercial paper

MetLife, Inc.—
-- AMB-1 (Outstanding) on commercial paper

The following Long-Term IRs have been affirmed with a stable outlook:

MetLife, Inc.—
-- “a-” (Excellent) on USD 1.0 billion 3.60% senior unsecured notes, due 2024
-- “a-” (Excellent) on GBP 350 million 5.375% senior unsecured notes, due 2024
-- “a-” (Excellent) on USD 500 million 3.60% senior unsecured notes, due 2025
-- “a-” (Excellent) on USD 500 million 3.0% senior unsecured notes, due 2025
-- “a-” (Excellent) on JPY 25.2 billion 0.495% senior unsecured notes, due 2026
-- “a-” (Excellent) on JPY 64.9 billion 0.769% senior unsecured notes, due 2029
-- “a-” (Excellent) on USD 1.0 billion 4.55% senior unsecured notes, due 2030
-- “a-” (Excellent) on JPY 10.7 billion 0.898% senior unsecured notes, due 2031
-- “a-” (Excellent) on USD 600 million 6.50% senior unsecured notes, due 2032
-- “a-” (Excellent) on USD 1.0 billion 5.375% senior unsecured notes, due 2033
-- “a-” (Excellent) on USD 750 million 6.375% senior unsecured notes, due 2034
-- “a-” (Excellent) on JPY 26.5 billion 1.189% senior unsecured notes, due 2034
-- “a-” (Excellent) on USD 1.0 billion 5.70% senior unsecured notes, due 2035
-- “a-” (Excellent) on JPY 24.4 billion 1.385% senior unsecured notes, due 2039
-- “a-” (Excellent) on USD 750 million 5.875% senior unsecured notes, due 2041
-- “a-” (Excellent) on USD 750 million 4.125% senior unsecured notes, due 2042
-- “a-” (Excellent) on USD 1.0 billion 4.875% senior unsecured notes, due 2043
-- “a-” (Excellent) on USD 500 million 4.721% senior unsecured debentures, due 2044
-- “a-” (Excellent) on USD 1.0 billion 4.05% senior unsecured notes, due 2045
-- “a-” (Excellent) on USD 750 million 4.6% senior unsecured notes, due 2046
-- “a-” (Excellent) on USD 1 billion 5.0% senior unsecured notes, due 2052
-- “a-” (Excellent) on USD 1 billion 5.25% senior unsecured notes, due 2054
-- “bbb” (Good) on USD 1.25 billion 6.40% junior subordinated debentures, due 2066
-- “bbb” (Good) on USD 500 million 10.75% junior subordinated debentures, due 2069
-- “bbb” (Good) on USD 600 million floating rate non-cumulative preferred stock, Series A
-- “bbb” (Good) on USD 500 million 5.875% non-cumulative preferred stock, Series D
-- “bbb” (Good) on USD 805 million 5.625% non-cumulative preferred stock, Series E
-- “bbb” (Good) on USD 1.0 billion 4.75% non-cumulative preferred stock, Series F
-- “bbb” (Good) on USD 1.0 billion 3.85% non-cumulative preferred stock, Series G

MetLife Capital Trust IV—
-- “bbb” (Good) on USD 700 million 7.875% exchangeable surplus trust securities (junior subordinated), due 2067

Metropolitan Life Insurance Company—
-- “a” (Excellent) on USD 250 million 7.80% surplus notes, due 2025
-- “a” (Excellent) on USD 150 million 7.875% surplus notes, due 2024 (originally issued by New England Mutual Life Insurance Company)

Metropolitan Life Global Funding I— “aa-” (Superior) program rating
-- “aa-” (Superior) on all outstanding notes issued under the program

The following indicative Long-Term IRs have been affirmed stable outlooks:

MetLife, Inc. —
-- “a-” (Excellent) on senior unsecured debt
-- “bbb+” (Good) on subordinated debt
-- “bbb” (Good) on preferred stock

This press release relates to Credit Ratings that have been published on AM Best’s website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best’s Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings. For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments.

AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

Copyright © 2024 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.

Louis Silvers

Senior Financial Analyst

+1 908 882 2316

louis.silvers@ambest.com



Jacqalene Lentz

Director

+1 908 882 2011

jacqalene.lentz@ambest.com



Christopher Sharkey

Associate Director, Public Relations

+1 908 882 2310

christopher.sharkey@ambest.com



Al Slavin

Senior Public Relations Specialist

+1 908 882 2318

al.slavin@ambest.com

Source: AM Best

FAQ

What is the Financial Strength Rating (FSR) of MetLife, Inc.?

The Financial Strength Rating (FSR) of MetLife, Inc. is A+ (Superior).

What are the Long-Term Issuer Credit Ratings (Long-Term ICR) of MetLife, Inc.?

The Long-Term Issuer Credit Ratings (Long-Term ICR) of MetLife, Inc. is 'aa-' (Superior).

What is the ticker symbol for MetLife, Inc.?

The ticker symbol for MetLife, Inc. is MET.

What is the outlook of MetLife, Inc.'s Credit Ratings?

The outlook of MetLife, Inc.'s Credit Ratings is stable.

What supports MetLife's strong balance sheet strength?

MetLife's strong balance sheet strength is supported by its consolidated holding company view of capital adequacy, financial flexibility, and liquidity of its ultimate parent (MetLife, Inc.).

MetLife, Inc.

NYSE:MET

MET Rankings

MET Latest News

MET Stock Data

59.89B
578.67M
16.41%
75.61%
0.84%
Insurance - Life
Life Insurance
Link
United States of America
NEW YORK